Whalesbook
Sabse pehle toh ye dollar ka funda samajhte hain. Jab dollar mahanga hota hai, toh India mein import hone wale raw materials jaise APIs aur chemicals bahut zyada expensive ho jaate hain. Experts keh rahe hain ki API se lekar packing tak, sab kuch dollar mein bikta hai, toh rupee jab girta hai toh pharma companies ki jeb pe bojh badh jaata hai.
Aur sirf dollar hi nahi, West Asia mein chal rahe conflict ki wajah se shipping bhi mahangi ho gayi hai aur supply chain mein bhi problems aa rahi hain. Government kuch chemicals par duty relief de rahi hai, par overall cost abhi bhi high hai.
Aur fir aata hai exports ka drama. March 2026 mein toh bhaisaab, pharma exports mein 23.17% ki girawat aayi, seedha $2.83 billion pe aa gaye. Pichhle teen saal mein pehli baar aisa hua hai ki ek mahine mein exports kam hue hain. Pura FY25-26 dekha toh thoda bahut growth hai, par March ka ye number bahut kuch bata raha hai.
Industry wale keh rahe hain ki demand ki kami nahi hai, asli problem logistics ki hai. West Asia mein problem se shipping routes disrupt ho gaye hain, Dubai se jaana mushkil ho gaya hai, delivery time badh gaya hai, aur mahangi dawaiyon ka risk bhi aa gaya hai. US aur Europe ke buyers bhi thoda cautiously deal kar rahe hain kyunki global economy slow chal rahi hai, toh orders delay ho rahe hain aur inventory bhi adjust kar rahe hain.
Ab is situation se nikalne ke liye companies ne ek naya game plan banaya hai. Pehle ye log low-margin wale generic drugs bechte the, par ab woh high-value, complex drugs jaise complex generics, biologics, biosimilars aur specialty drugs pe focus kar rahe hain. Inki prices achhi milti hain aur patents bhi lambe chalte hain.
Iske liye companies R&D aur advanced manufacturing mein zyada paisa laga rahi hain. PLI jaise government schemes bhi local API production ko boost kar rahi hain. Nifty Pharma index toh thoda dip hone ke baad bhi market se better perform kar raha hai. Sector ki total market value ₹19.29 lakh crore hai aur P/E ratio 38.7 hai, jo investor ka confidence dikhata hai. Kai companies pe debt bhi kam hai jo in R&D efforts ko support kar raha hai.
Par bhai, itna aasan nahi hai ye shift. Abhi bhi hum APIs ke liye import pe bahut depend karte hain, khas kar China se, toh supply chain aur currency fluctuations ka risk bana hua hai. West Asia ka conflict us vulnerability ko aur highlight karta hai, jisse prices badh sakti hain aur dawaiyon ki shortage bhi ho sakti hai.
US FDA, EMA jaise strict global rules follow karne mein bahut paisa lagta hai. Analysts keh rahe hain ki generics ka profit kam ho raha hai, toh agar high-value drugs mein success nahi mila toh profits gir sakte hain. US tariffs ka bhi risk hai.
Overall, analysts ko FY2026 mein 7-9% growth expected hai, mainly domestic aur Europe se. US mein growth thoda slow ho sakta hai. Profit margins theek rehne ki ummeed hai kyunki specialty products badh rahe hain. Long term mein, 2030 tak Indian pharma sector $120 billion se $130 billion tak pahunch sakta hai. Ye sab depend karta hai regulatory hurdles manage karne pe, innovation pe aur supply chain risks kam karne pe. Ab companies sirf low cost nahi, quality aur reliability pe focus kar rahi hain. Par global geopolitical risks aur economic slowdown is plan ko test karenge.